Structure Therapeutics Inc American Depositary Shares

Structure Therapeutics Inc American Depositary Shares

Yahoo Finance • 9 days ago

Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?

Novo NVO announced two important regulatory updates in Europe late last week, putting its Rare Disease portfolio back in focus. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of d... Full story

Yahoo Finance • 10 days ago

Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results

Quick Read Viking Therapeutics surged 26% after VK2735 maintenance data validated monthly and every-other-week dosing schedules, directly addressing the adherence problem plaguing injectable GLP-1s. Obesity peers shrugged at the results,... Full story

Yahoo Finance • 15 days ago

LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

Eli Lilly and Company's LLY stock has declined around 7.2% in the past month after gaining sharply earlier in 2026 and trading near record levels. At around 26.3x forward earnings, LLY continues to command a premium valuation, making the s... Full story

Yahoo Finance • 15 days ago

Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?

Novo NVO recently entered a new chapter by adopting "Novo" as its day-to-day name, as it seeks to sharpen its focus and competitiveness amid slowing growth and intensifying market competition. The move comes as the stock faces growing inve... Full story

Yahoo Finance • 18 days ago

Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?

Novo NVO stock declined 2.1% on Friday as a Morgan Stanley downgrade added fresh pressure. The investment bank reportedly cut NVO to "Underweight" from "Equal-weight" while retaining a $40 (DKK 250) price target, arguing that the valuation... Full story

Yahoo Finance • 24 days ago

Structure Therapeutics falls after trial data for lead obesity drugs

[Injection pen with measuring tape and pills on white background, concept of weight loss, GLP-1 treatment, diet supplements and healthcare] OMaltseva/iStock via Getty Images Structure Therapeutics (GPCR [https://seekingalpha.com/symbol/GP... Full story

Yahoo Finance • 24 days ago

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

Novo Nordisk NVO announced positive data from the phase III STEP Young study evaluating once-weekly subcutaneous semaglutide, in combination with a reduced-calorie diet and increased physical activity, in children with obesity aged six to... Full story

Yahoo Finance • 24 days ago

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Structure Therapeutics Inc. ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clin... Full story

Yahoo Finance • last month

Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?

Novo Nordisk NVO is counting on CagriSema as one of its most important next-generation cardiometabolic assets. The once-weekly injectable combines the long-acting amylin analog cagrilintide 2.4 mg with its blockbuster GLP-1 RA Wegovy (inje... Full story

Yahoo Finance • last month

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as notable companies in the obesity and metabolic disease space, both focused on the growing opportunity in GLP-1 therapies. Novo Nordisk is a global leader in the category, ma... Full story

Yahoo Finance • 3 months ago

The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea

The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures. A single clinical result can send a stock soaring, wipe out years of gains, or threaten the company itself. Drug develo... Full story

Yahoo Finance • 3 months ago

After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching

Quick Read Legend Biotech (LEGN) generates $1 billion in CAR-T revenue with J&J already embedded as acquirer, yet trades at roughly half its $58 analyst price target. Aleniglipron posted 16% placebo-adjusted weight loss at 44 weeks, placi... Full story

Yahoo Finance • 4 months ago

H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ:GPCR) from $100 to $70, which still l... Full story

Yahoo Finance • 4 months ago

GLP-1 Sales Forecast Jumps To $150 Billion By 2030

This article first appeared on GuruFocus. TD Cowen has lifted its global GLP-1 sales forecast to $150 billion by 2030, up from its prior $139 billion estimate issued just over a year ago, signaling that demand for the drug class populariz... Full story

Yahoo Finance • 4 months ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesi... Full story

Yahoo Finance • 4 months ago

If Viking Therapeutics Is Acquired, Here’s Who Wins

Quick Read Viking Therapeutics (VKTX) is the most closely watched biotech acquisition target. A buyer such as Eli Lilly (LLY) would benefit, as would Viking shareholders, and at least one GLP-1 competitor. The analyst who called NVIDIA in... Full story

Yahoo Finance • 4 months ago

Monashee Scales Back Its Bet on Structure Therapeutics

Key Points Monashee sold 175,000 Structure Therapeutics shares; estimated trade size approximately $11.98 million based on the mean unadjusted close for the quarter. Quarter-end position value dropped by $13.24 million, reflecting both sa... Full story

Yahoo Finance • 5 months ago

Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best biotech stocks with highest upside potential. As of April 24 closing, the stock carries a strongly bullish consensus sentiment, receiving Buy ratings from all 14 analysts. Ba... Full story

Yahoo Finance • 6 months ago

Guggenheim Remains Bullish on Eli Lilly (LLY) Ahead of Q1 2026 Results

Eli Lilly and Company (NYSE:LLY) is included in our list of the 14 hedge fund favorites with strong setup in 2026.Guggenheim Remains Bullish on Eli Lilly (LLY) Ahead of Q1 2026 Results On March 30, 2026, Guggenheim updated its model ahead... Full story

Yahoo Finance • 6 months ago

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Quick Read The GLP-1 wave has triggered a broader biopharma M&A cycle extending well beyond obesity drugs. These five biotech companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline... Full story